Israel is an entrepreneur, engineer, and inventor of the Cognalyzer® neurotechnology.
In 2015, Israel had the vision of developing the first true test for quantifying the effects drugs have on the brain rather than simply measuring substance concentration levels in body fluids (blood, urine, saliva, breath)
In 2021, after 6 years of raising capital and building an interdisciplinary team, Israel made his vision a reality with the development and commercialization of the Cognalyzer® neurotechnology platform.
The Cognalyzer® is the only solution in the market that is capable of objectively quantifying the actual effects of drugs based on EEG analysis, using scientifically validated AI models that predict drug effects at unprecedented accuracy.
Israel’s new vision is to transform the global drug testing market with the groundbreaking research capability of the Cognalyzer®.
This transformation has already started with the commercialization of the Cognalyzer® in the cannabis effect research market from 2021. Licensed producers use Cognalyzer-derived cannabis effect data to optimize the way they formulate, validate, promote, and sell their products.
Israel is an entrepreneur, engineer, and inventor of the Cognalyzer® neurotechnology.
In 2015, Israel had the vision of developing the first true test for quantifying the effects drugs have on the brain rather than simply measuring substance concentration levels in body fluids (blood, urine, saliva, breath)
In 2021, after 6 years of raising capital and building an interdisciplinary team, Israel made his vision a reality with the development and commercialization of the Cognalyzer® neurotechnology platform.
The Cognalyzer® is the only solution in the market that is capable of objectively quantifying the actual effects of drugs based on EEG analysis, using scientifically validated AI models that predict drug effects at unprecedented accuracy.
Israel’s new vision is to transform the global drug testing market with the groundbreaking research capability of the Cognalyzer®.
This transformation has already started with the commercialization of the Cognalyzer® in the cannabis effect research market from 2021. Licensed producers use Cognalyzer-derived cannabis effect data to optimize the way they formulate, validate, promote, and sell their products.
17011 Beach Blvd, Suite 500 Huntington Beach, CA 92647
714-847-3540© 2025 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy